Evidence map›Paper›PMID 41608526›Full record

ArticleResearch (Washington, D.C.)2026

Transarterial Chemoembolization Modulates the Exosomal miR-32-5p/cGAS-STING Axis Mediated Macrophage Ferroptosis, Triggers Immune Remodeling, and Enhances Anti-PD-1/L1 Efficacy in HCC.

Bufu Tang, Dandan Guo, Weiliang Hou, Wen Zhang, Wei Zhang, Jingqin Ma, Changyu Li, Guowei Yang, Lin Zhu, Min Li and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bufu TangDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Dandan GuoDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
Weiliang HouDepartment of Gastroenterology, Shanghai Institute of Pancreatic Diseases, National Key Laboratory of Immunity and Inflammation, Changhai Clinical Research Unit, Changhai Hospital, Naval Medical University, Shanghai, China.
Wen ZhangDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Wei ZhangDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Jingqin MaDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Changyu LiDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Guowei YangDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Lin ZhuDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Min LiDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Xuran JinDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Zhiping YanDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Qianqian ZhaoDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yongjie ZhouDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Xudong QuDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-1222-3036

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a cancer type that causes a high rate of cancer death in the world. The standard therapy plan of intermediate and advanced stages of the HCC is transarterial chemoembolization (TACE). The treatment effectiveness is, however, limited because of the heterogeneity of tumors and the resistance to drugs. This paper shows that the HCC patients with TACE resistance alter their tumor immune homeostasis by reducing the secretion of exosomal miR-32-5p, which has a negative relationship with the population of CD68

Identifiers

PMID41608526
PMCPMC12835496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.